Cadila Healthcare announced that Zydus group has launched the breakthrough oral therapy, SoviHep which will provide succor to more than 10 million patients who suffer from Hepatitis C in India.

The therapy will be marked by the specialty division of the group, Zydus Heptiza.

Zydus and Gilead Sciences had signed a non-exclusive licensing agreement which will allow the manufacture of sofosbuvir and the fixed-dose combination of ledipasvir/sofosbuvir for distribution in 91 countries including India.

Pankaj R Patel, chairman and managing director of the Zydus group said, "Innovations in healthcare have made it possible to deliver better therapy outcomes and improve quality of lives. We are happy to partner with Gilead Sciences to make this breakthrough therapy accessible to patients of Hepatitis C in India. It bridges a longstanding unmet healthcare need. It also underlines our mission of providing access to new, affordable therapies and we stand committed to this."  

Shares of the company gained Rs 3.95, or 0.25%, to trade at Rs 1,589.90. The total volume of shares traded was 9,876 at the BSE (1 p.m., Tuesday).